Medipost Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6
Ending by 2030
Mar 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 21 to 26, 2026 · next Nov 21
- 1 fee due Dec 4, 2026The maintenance fee for Pharmaceutical composition for the prevention or treatment of a pulmonary disorder comprising mesenchymal stem cells having improved proliferation and differentiation capacity (US 10,307,442) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,655,778 | SISP-1, a Novel P53 Target Gene and Use Thereof In force · High confidence | In force | High confidence | |
| US 9,498,497 | Method of treating lung diseases using cells separated or proliferated from umbilical cord blood In force · From the USPTO record | In force | From the USPTO record | |
| US 9,439,931 | Administering umbilical cord blood-derived mesenchymal stem cells to treat nerve injury In force · From the USPTO record | In force | From the USPTO record | |
| US 10,238,692 | Composition Comprising a Culture Solution of Mesenchymal Stem Cells for the Treatment of Neural Diseases In force · High confidence | In force | High confidence | |
| US 9,387,226 | Neural cell proliferation induced through the culture of neural cells with umbilical cord blood-derived mesenchymal stem cells In force · From the USPTO record | In force | From the USPTO record | |
| US 9,408,892 | Treating cartilage defect with UCB-MSC expressing TSP-2 In force · From the USPTO record | In force | From the USPTO record | |
| US 8,614,191 | Use of ICAM-1 for prevention or treatment of neurological diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 9,040,298 | Method of selecting stem cells having high chondrogenic differentiation capability In force · From the USPTO record | In force | From the USPTO record | |
| US 9,580,687 | Method for culturing mesenchymal stem cells In force · From the USPTO record | In force | From the USPTO record | |
| US 10,294,456 | Method for culturing mesenchymal stem cells In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 15: 1 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 11 no status recorded